Aislinn Antrim is an associate editor at Pharmacy Times®. She graduated from the University of North Carolina at Chapel Hill in 2019 and is completing her master’s in communication and media at Rutgers University.
Risankizumab Demonstrates Significant Improvements In Patients with Crohn Disease
January 11th 2021A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.
Read More